ENYO Pharma selected to take part in the French Tech 120 FT120 program

Published on 08/02/2021

ENYO Pharma has been selected to take part in the French Tech 120 #FT120 program for the second consecutive year. We will thus benefit from specific guidance and visibility. Created by the French government, this program offers support to French scaleups with the potential to become global technology leaders.

https://lafrenchtech.com/en/how-france-helps-startups/ft120/

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH